People News

Share this article:

Former Pfizer president of global R&D John LaMattina, PhD, has joined Boston-based venture firm PureTech Ventures as senior partner.  The move follows yesterday's announcement that Pfizer was splitting leadership of its R&D operations into a biotherapeutics division, headed by Mikael Dolsten, and a pharmatherapeutics division, headed by Martin Mackay. LaMattina spent 30 years at Pfizer.

Santen CEO Adrienne Graves has been appointed to the board of directors of the Glaucoma Research Foundation. Graves leads the US subsidiary of Japan's Santen Pharmaceutical Co., a leading manufacturer of prescription ophthalmic drugs globally.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in People Moves

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in People Moves

Monday Moves: October 20

Promotions and hires for agencies and manufacturers

Monday Moves: September 29

Promotions and hires for agencies and manufacturers

Monday Moves—July 21, 2014

Hires and promotions for Manufacturers, Agencies and Media